An aerial photo of Pendik port in Asian side of Istanbul, Friday, June 4, 2021, with a huge mass of marine mucilage, a thick, slimy substance made up of compounds released by marine organisms, in Turkey's Marmara Sea. Turkey's President Recep Tayyip Erdogan promised Saturday to rescue the Marmara Sea from an outbreak of "sea snot" that is alarming marine biologists and environmentalists. Erdogan said untreated waste dumped into the Marmara Sea and climate change had caused the sea snot bloom. Istanbul, Turkey's largest city with some 16 million residents, factories and industrial hubs, borders the sea.(AP Photo)
Turkey’s president promised Saturday to rescue the Marmara Sea from an outbreak of “sea snot” that is alarming marine biologists and environmentalists.
A huge mass of marine mucilage, a thick, slimy substance made up of compounds released by marine organisms, has bloomed in Turkey's Marmara, as well as in the adjoining Black and Aegean Seas.
Turkish President Recep Tayyip Erdogan said untreated waste dumped into the Marmara Sea and climate change had caused the sea snot bloom. Istanbul, Turkey’s largest city with some 16 million residents, and five other provinces, factories and industrial hubs border the sea.
Marine mucilage has reached unprecedented levels this year in Turkey. It is visible above the water as a slimy gray sheet along the shores of Istanbul and neighboring provinces. Underwater videos showed suffocated coral covered with sea snot.
Erdogan said he instructed the Ministry of Environment and Urbanization to coordinate with relevant institutions, municipalities and universities. Teams are inspecting waste water and solid waste facilities, along with other potential sources of pollution, he said.
“We will save our seas from this mucilage calamity, leading with the Marmara Sea,” Erdogan said. “We must take this step without delay.”
Marine experts say that human waste and industrial pollution is choking Turkey’s seas. They say the rise in water temperatures from climate change is contributing to the problem.
Healthcare workforce management platform ShiftMed
recently announced a $45 million funding round.
The company's platform connects nurses and healthcare professionals to hospitals and other healthcare providers.
ShiftMed's new funding comes amid widespread labor shortages in the healthcare sector. The company's CEO Todd Walrath joins Cheddar News' Closing Bell to discuss.
Universities like UCLA, Yale, and Duke have announced they're implementing remote learning amid the COVID omicron variant surge, despite President Biden recommending that K-12 schools should continue in-person education. Jared C. Bass, senior director for Higher Education at American Progress, joined Cheddar to break down what institutions of higher education might be considering differently. "I think some universities are allowing periods of a bit of a respite to allow students to get testing and make sure when they do return back to campus that they're healthy," he noted.
Supply chain issues have become one of the biggest roadblocks for the U.S. EV market, with production woes likely to stunt the industry's growth in 2022. Rich Steinberg, electric vehicle expert and industry advisor, told Cheddar that the Biden administration investing in domestic mining for essential minerals used in battery manufacturing — such as lithium — could help alleviate the bottlenecks. "Some of those same materials are available domestically, they just haven't been prioritized," he said, noting the paradox between green tech and "dirty" mining. "The good news is that there are ways to extract those materials cleanly."
Hyperfine, the pioneer of the very first FDA-approved portable MRI device, made its public debut on the Nasdaq via a SPAC merger. CEO Dave Scott joined Cheddar's "Opening Bell" to discuss the IPO launch, the company's valuation at $580 million, and the impact of its machine called Swoop. "We can roll an MRI system, our MRI Swoop system, right into the room where you are, right up to your patient bedside, and scan you right there and get an image in less than an hour," he explained.
Dr. Rob Davidson, Executive Director of the Committee to Protect Health Care and an ER Physician in West Michigan, joins Cheddar News to break down the expectations of Pfizer's new COVID-19 treatment pill.
The FDA has granted emergency use authorization to Pfizer's pill to treat covid-19. The treatment, called Paxlovid, is the first antiviral covid-19 pill that people can take at home.
Pfizer says the pill can reduce the risk of severe illness by 90 percent and is intended for people at high risk for severe disease, including those over 65, people with obesity, diabetes, or a weakened immune system. Professor Peter Pitts, Founder, Center for Medicine in the Public Interest & Former FDA Associate joined Wake Up with Cheddar to discuss.
Ahead of a four day week for the markets due to the upcoming Christmas holiday, investors hoping for a quiet end to the year, or even a Santa Claus rally, may not be in luck. Investors are still digesting the latest from the Fed regarding a quicker than expected taper, as well as ever increasing blow back as the Omicron variant spreads. Octavio Marenzi, CEO of Opimas LLC, explains why the markets have been so volatile ever since the emergence of the latest variant and what to expect going forward into 2022.
Carlo and Baker cover the heartening news on the Covid front ahead of the holiday, plus President Biden punting student loan repayments again, a new space telescope and Love, Hate, Ate: Christmas Eve Eve Edition!
Pfizer, one of the makers of a currently available COVID-19 vaccine, has taken another critical step forward in combatting the pandemic by getting regulatory approval for Paxlovid, a pill treatment rather than IV or injection as others have been. Dr. Purvi Parikh, an immunologist with the Allergy and Asthma Network, spoke to Cheddar about the ramifications of the authorization. "This is huge, especially because we know early treatment does keep people out of the hospital, especially with this antiviral," Parikh said. "The fact that people can start a regimen at home so they don't have to leave and further expose others is a big breakthrough." She also explained how the drug is a combination of two antiviral medications that are not without its risks but should be safe over the short term.
This year's worldwide semiconductor shortage limited the supply of everything from new cars to smartphones; and now, many in the chip industry expect the shortage to continue deep into 2022, and maybe even 2023. Semiconductor senior research analyst for Robert W. Baird & Co., Tristan Gerra, joins Cheddar News' Closing Bell to discuss.
